TG Therapeutics, Inc. (NASDAQ:TGTX), an innovative, clinical-stage biopharmaceutical company announced preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA™), the oral BTK inhibitor from Pharmacyclics/Janssen. Data from the Phase 2 study is being presented during the 19th Annual European Hematology Association (EHA) meeting being held in Milan, Italy. TG Therapeutics, Inc. (NASDAQ:TGTX) weekly performance is 47.85%. On last trading day company shares ended up $9.61. Analysts mean target price for the company is $11.67. TG Therapeutics, Inc. (NASDAQ:TGTX) distance from 50-day simple moving average is 68.04%.
InterMune (NASDAQ:ITMN) has earned an average rating of “Buy” from the sixteen analysts that are currently covering the stock. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company InterMune Inc (NASDAQ:ITMN) shares advanced 1.30% in last trading session and ended the day on $44.46. ITMN Gross Margin is 87.30% and its return on assets is -44.50%. InterMune Inc (NASDAQ:ITMN) quarterly performance is 38.55%.
Vital Therapies (NYSE:VTL) issued its quarterly earnings data on Tuesday. The company reported ($24.49) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.54) by $23.95.Vital Therapies Inc (NASDAQ:VTL) shares moved up 0.09% in last trading session and was closed at $32.11, while trading in range of $30.12-$35.20. Vital Therapies Inc (NASDAQ:VTL) year to date performance is 167.83%.
Bernstein began coverage on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report released on Wednesday. The firm issued an outperform rating and a $30.00 price objective on the stock.Alder Biopharmaceuticals Inc (NASDAQ:ALDR) ended the last trading day at $20.34. Company weekly volatility is calculated as 11.62% and price to cash ratio as 26.21. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) showed a positive weekly performance of 29.39%.
Research analysts at BMO Capital Markets lifted their price target on shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) from $21.00 to $34.00 in a report released on Monday. Applied Genetic Technologies Corp (NASDAQ:AGTC) weekly performance is 28.34%. On last trading day company shares ended up $27.49. Analysts mean target price for the company is $22.75. Applied Genetic Technologies Corp (NASDAQ:AGTC) distance from 50-day simple moving average is 84.08%.